Callan Capital LLC Buys New Stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB)

Callan Capital LLC acquired a new stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 14,361 shares of the company's stock, valued at approximately $281,000.

Several other institutional investors have also bought and sold shares of the business. Bank of New York Mellon Corp lifted its holdings in shares of Genmab A/S by 4.0% in the 4th quarter. Bank of New York Mellon Corp now owns 71,623 shares of the company's stock worth $1,495,000 after acquiring an additional 2,749 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Genmab A/S by 134.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 61,177 shares of the company's stock worth $1,277,000 after acquiring an additional 35,073 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Genmab A/S in the 4th quarter worth about $2,463,000. Callan Family Office LLC bought a new stake in shares of Genmab A/S in the 4th quarter worth about $225,000. Finally, Sequoia Financial Advisors LLC lifted its holdings in shares of Genmab A/S by 27.8% in the 4th quarter. Sequoia Financial Advisors LLC now owns 22,204 shares of the company's stock worth $463,000 after acquiring an additional 4,835 shares during the last quarter. Institutional investors own 7.07% of the company's stock.

Genmab A/S Stock Down 2.1%

Shares of Genmab A/S stock traded down $0.46 on Friday, reaching $21.40. The stock had a trading volume of 1,247,549 shares, compared to its average volume of 1,250,780. The company has a 50 day moving average price of $21.04 and a 200 day moving average price of $20.75. Genmab A/S Sponsored ADR has a 1 year low of $17.24 and a 1 year high of $28.56. The stock has a market capitalization of $13.73 billion, a P/E ratio of 12.16, a P/E/G ratio of 6.65 and a beta of 0.94.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.23 by $0.08. Genmab A/S had a net margin of 35.11% and a return on equity of 18.08%. The firm had revenue of $715.00 million for the quarter, compared to the consensus estimate of $5.17 billion. On average, analysts forecast that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently commented on GMAB shares. HC Wainwright reaffirmed a "buy" rating and issued a $37.00 price target (down previously from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. Wall Street Zen raised shares of Genmab A/S from a "hold" rating to a "buy" rating in a research note on Saturday. Sanford C. Bernstein downgraded shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research note on Tuesday, April 1st. Finally, Truist Financial raised their price target on shares of Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $37.80.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.